KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Liabilities and Shareholders Equity (2016 - 2026)

West Pharmaceutical Services has reported Liabilities and Shareholders Equity over the past 18 years, most recently at $4.1 billion for Q1 2026.

  • Quarterly Liabilities and Shareholders Equity rose 13.59% to $4.1 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $16.4 billion through Mar 2026, up 13.95% year-over-year, with the annual reading at $4.3 billion for FY2025, 17.2% up from the prior year.
  • Liabilities and Shareholders Equity was $4.1 billion for Q1 2026 at West Pharmaceutical Services, down from $4.3 billion in the prior quarter.
  • Over five years, Liabilities and Shareholders Equity peaked at $4.3 billion in Q4 2025 and troughed at $3.3 billion in Q1 2022.
  • The 5-year median for Liabilities and Shareholders Equity is $3.7 billion (2023), against an average of $3.7 billion.
  • Biggest five-year swings in Liabilities and Shareholders Equity: increased 20.26% in 2022 and later fell 4.91% in 2024.
  • Tracing WST's Liabilities and Shareholders Equity over 5 years: stood at $3.6 billion in 2022, then rose by 5.88% to $3.8 billion in 2023, then fell by 4.86% to $3.6 billion in 2024, then increased by 17.2% to $4.3 billion in 2025, then dropped by 3.75% to $4.1 billion in 2026.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $4.1 billion, $4.3 billion, and $4.1 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.